Microneedle-Based Intradermal Delivery Enables Rapid Lymphatic Uptake and Distribution of Protein Drugs

ABSTRACTPurposeThe purpose of this research was to examine the pharmacokinetics (PK) of drug uptake for microneedle-based intradermal (ID) delivery of several classes of protein drugs compared to standard subcutaneous (SC) administration.MethodsSystemic absorption kinetics of various proteins were analyzed following microneedle-based ID delivery and standard injection methods in the swine model. Comparative PK data were determined using standard non-compartmental techniques based on blood serum levels.ResultsDelivery of proteins using microneedles resulted in faster systemic availability, measured via tmax, and increased maximal drug concentration, Cmax, over SC delivery for all proteins tested. Some agents also exhibited increased bioavailability for the ID route. Imaging studies using reporter dyes showed rapid lymphatic-mediated uptake.ConclusionsMicroneedle delivery is applicable to a wide variety of protein drugs and is capable of effective parenteral administration of therapeutic drug dosages. This delivery route alters absorption kinetics via targeting a tissue bed better perfused with lymphatic and blood vessels than the SC space. Microneedle delivery may afford various advantages, including a robust method to increase the absorption rate and bioavailability of proteins that have been challenging to deliver at therapeutic levels or with physiologically relevant profiles.

[1]  N. Mickuvienė,et al.  Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial , 2009, BMC medicine.

[2]  Leonid Kagan,et al.  The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  G. Kasting,et al.  Dermal Capillary Clearance: Physiology and Modeling , 2005, Skin Pharmacology and Physiology.

[4]  Leonard A. Smith,et al.  An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock , 2008, Journal of immune based therapies and vaccines.

[5]  Erik Mosekilde,et al.  Absorption kinetics of insulin after subcutaneous administration. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  A. Bollinger.  Microlymphatics of human skin. , 1993, International journal of microcirculation, clinical and experimental.

[7]  T Wurch,et al.  Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation. , 2008, Current pharmaceutical biotechnology.

[8]  C. Porter,et al.  Subcutaneous drug delivery and the role of the lymphatics. , 2005, Drug discovery today. Technologies.

[9]  H. Hamilton.  Complications associated with venous access devices:part one. , 2006, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[10]  Laurent Simon,et al.  Dynamics and control of percutaneous drug absorption in the presence of epidermal turnover. , 2009, Journal of pharmaceutical sciences.

[11]  M. Swartz,et al.  The Role of Interstitial Stress in Lymphatic Function and Lymphangiogenesis , 2002, Annals of the New York Academy of Sciences.

[12]  H. Maibach,et al.  Percutaneous Penetration Enhancers: An Overview , 2007, Skin Pharmacology and Physiology.

[13]  H. Hamilton.  Complications associated with venous access devices:part two. , 2006, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[14]  Cheryl H. Dean,et al.  Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccines against Japanese Encephalitis (ChimeriVaxTM-JE) in Non-Human Primates , 2005, Human vaccines.

[15]  H Gin,et al.  Reproducibility and variability in the action of injected insulin. , 2005, Diabetes & metabolism.

[16]  B. Guerci,et al.  Subcutaneous insulin: pharmacokinetic variability and glycemic variability. , 2005, Diabetes & metabolism.

[17]  G. Edwards,et al.  Lymphatic Absorption Is a Significant Contributor to the Subcutaneous Bioavailability of Insulin in a Sheep Model , 2001, Pharmaceutical Research.

[18]  Kang-Choon Lee,et al.  Emerging PEGylated drugs , 2009, Expert opinion on emerging drugs.

[19]  P. Laurent,et al.  Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. , 2007, Vaccine.

[20]  Wijaya Martanto,et al.  Mechanism of fluid infusion during microneedle insertion and retraction. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Vincent J. Sullivan,et al.  Microneedle-Based Intradermal Delivery of the Anthrax Recombinant Protective Antigen Vaccine , 2006, Infection and Immunity.

[22]  A. Morrissey,et al.  Clinical administration of microneedles: skin puncture, pain and sensation , 2009, Biomedical microdevices.

[23]  H. Peter,et al.  The lymph vessel network in mouse skin visualised with antibodies against the hyaluronan receptor LYVE-1. , 2008, Immunobiology.

[24]  Y. Kalia,et al.  Transdermal drug delivery: overcoming the skin's barrier function. , 2000, Pharmaceutical science & technology today.

[25]  N. Harvey,et al.  Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines , 2007, Clinical and Vaccine Immunology.

[26]  E. Donadio,et al.  Antibodies for therapeutic uses and the evolution of biotechniques. , 2009, Current medicinal chemistry.

[27]  Mark R Prausnitz,et al.  Microneedles for transdermal drug delivery. , 2004, Advanced drug delivery reviews.

[28]  Lisa C. Zaba,et al.  Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.

[29]  S. Brunton.  Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. , 2008, The American journal of medicine.

[30]  P. Rhodes.  Administration. , 1933, Teachers College Record: The Voice of Scholarship in Education.

[31]  P. Laurent,et al.  Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook , 2008, Expert review of vaccines.

[32]  Shi Ke,et al.  Quantitative imaging of lymph function. , 2007, American journal of physiology. Heart and circulatory physiology.

[33]  L. Illum,et al.  Intranasal delivery: physicochemical and therapeutic aspects. , 2007, International journal of pharmaceutics.

[34]  Vincent J. Sullivan,et al.  Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. , 2005, The Journal of infectious diseases.

[35]  J. Villadangos,et al.  Antigen presentation by dendritic cells in vivo. , 2009, Current opinion in immunology.

[36]  Mark G. Allen,et al.  Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  F. de Looze,et al.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. , 2008, The Journal of infectious diseases.

[38]  Marva Waldron.  Sickle cell disorders. , 2006, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[39]  Y. Chien,et al.  Comparative pharmacokinetic and pharmacodynamic studies of human insulin and analogues in chronic diabetic Yucatan minipigs. , 1998, The Journal of pharmacology and experimental therapeutics.

[40]  P. Lambert,et al.  Intradermal vaccine delivery: will new delivery systems transform vaccine administration? , 2008, Vaccine.

[41]  M. Saville,et al.  Improving seasonal and pandemic influenza vaccines , 2008, Influenza and other respiratory viruses.

[42]  Vincent J. Sullivan,et al.  Protective Immunity in Mice Achieved with Dry Powder Formulation and Alternative Delivery of Plague F1-V Vaccine , 2009, Clinical and Vaccine Immunology.

[43]  C. Gravholt,et al.  Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. , 2001, The Journal of clinical endocrinology and metabolism.

[44]  S. Shoyele,et al.  Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. , 2006, International journal of pharmaceutics.

[45]  E. Haus,et al.  Chronobiology in the endocrine system. , 1989, Advanced drug delivery reviews.

[46]  M. Prausnitz,et al.  Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. , 2009, Diabetes technology & therapeutics.

[47]  Milton V. Marshall,et al.  Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. , 2008, Radiology.

[48]  S. Garg,et al.  Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. , 2009, Diabetes technology & therapeutics.

[49]  L. Heinemann,et al.  Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects , 1994, Diabetologia.

[50]  G. Leroux-Roels,et al.  Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. , 2008, Vaccine.